Combination of sulindac and antimicrobial eradication of Helicobacter pylori prevents progression of gastric cancer in hypergastrinemic INS-GAS mice.

@article{Lee2009CombinationOS,
  title={Combination of sulindac and antimicrobial eradication of Helicobacter pylori prevents progression of gastric cancer in hypergastrinemic INS-GAS mice.},
  author={C. Lee and B. Rickman and A. Rogers and S. Muthupalani and S. Takaishi and P. Yang and T. Wang and J. Fox},
  journal={Cancer research},
  year={2009},
  volume={69 20},
  pages={
          8166-74
        }
}
Helicobacter pylori infection causes severe dysplasia manifested as gastrointestinal intraepithelial neoplasia (GIN) after 28 weeks post-H. pylori infection (WPI) in cancer-prone, hypergastrinemic male INS-GAS mice. We examined the efficacy of the nonsteroidal anti-inflammatory drug sulindac (400 ppm in drinking water) alone, the CCK2/gastrin receptor antagonist YM022 (45 mg/kg/wk) alone, and sulindac or YM022 combined with H. pylori eradication therapy to prevent H. pylori-associated gastric… Expand
47 Citations
Lack of commensal flora in Helicobacter pylori-infected INS-GAS mice reduces gastritis and delays intraepithelial neoplasia.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 55 REFERENCES
Helicobacter pylori-associated gastric cancer in INS-GAS mice is gender specific.
Synergistic interaction between hypergastrinemia and Helicobacter infection in a mouse model of gastric cancer.
Synergistic inhibitory effects of gastrin and histamine receptor antagonists on Helicobacter-induced gastric cancer.
Anti-inflammatory effect of two isoforms of COX in H. pylori-induced gastritis in mice: possible involvement of PGE2.
...
1
2
3
4
5
...